ClinicalTrials.gg
Not yet recruitingNCT07846592FLASHUpdated Sep 29, 2026

Real-time Fluorescence Microscopy for Intraoperative Assessment of Prostate Biopsy Cores (FLASH)

An observational study in Prostate Cancer (Diagnosis) and Prostatic Neoplasms, sponsored by Shanghai East Hospital. Not yet recruiting. Open to male participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Shanghai East Hospital · Observational

Updated Sep 29, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
450
Ages
40 Years and older
Sex
Male
01

Study summary

Current prostate cancer diagnosis relies on MRI-targeted biopsy combined with a 12-core systematic biopsy. The systematic component is a major driver of overdiagnosis of insignificant cancer and biopsy-related morbidity, and conventional pathology takes 1-2 weeks, causing significant patient anxiety. The EndoScell system is a handheld, real-time fluorescence microscope that can display the microscopic structure of a fresh biopsy core within minutes, without damaging the tissue.

In this study, every biopsy core from men undergoing standard combined (targeted plus systematic) prostate biopsy will be scanned with this device immediately after removal, and the result will be compared with the final conventional pathology report of the very same core. The device result will not be used to guide any patient care. The study will measure how accurate the device is and simulate how many systematic biopsies could safely be avoided in the future if a positive device reading were used to stop further sampling.

Read the detailed description

FLASH is an investigator-initiated, international, multicentre, prospective diagnostic-accuracy and clinical-utility study with a within-patient paired design, conducted and reported in accordance with STARD 2015. Biopsy-naïve men with suspected prostate cancer (serum PSA >4 ng/mL and/or abnormal digital rectal examination) and at least one MRI-visible lesion (PI-RADS v2.1 score 3-5) will undergo standard-of-care combined targeted and systematic prostate biopsy.

Immediately after extraction, every core will undergo ex vivo dual staining (fluorescein sodium for 30 seconds followed by methylene blue for 30 seconds) and contact-mode scanning with the EndoScell real-time fluorescence microscope (model MES-1000P), completed within 5 minutes per core by certified technicians. Each core is assigned to a three-tier category (0 = negative/suspected low-grade; 1 = suspected clinically significant prostate cancer; 2 = equivocal). The interval from core extraction to formalin fixation will not exceed 15 minutes. All cores then undergo routine formalin-fixed paraffin-embedded (FFPE) histopathology with haematoxylin and eosin staining, with immunohistochemistry as clinically indicated, reported by senior uropathologists.

Bidirectional blinding is enforced throughout: technicians are blinded to all clinical data, MRI findings, and core origin; device results are withheld from the treating team and never enter the medical record; uropathologists are blinded to all device data; the statistician works with coded variables until database lock. Central pathology review is performed for discordant and equivocal cases.

The primary outcome is patient-level diagnostic accuracy (sensitivity, specificity, positive and negative predictive values with exact 95% confidence intervals) of the device for clinically significant prostate cancer (ISUP grade group >=2) against FFPE histopathology in the intention-to-diagnose population. Secondary outcomes include core-level concordance with cluster adjustment, inter-reader reproducibility, tissue-integrity assessment, operational metrics, and a prespecified decision-analytic simulation of a "Positive-then-Stop" biopsy-sparing pathway, which is hypothesis-generating and does not alter patient care. The accuracy and utility estimates are intended to inform the design of a future randomised de-implementation trial.

02

Conditions studied

  • Prostate Cancer (Diagnosis)
  • Prostatic Neoplasms

Keywords

  • fluorescence microscopy
  • diagnostic accuracy
  • prostate biopsy
  • multiparametric MRI
  • clinically significant prostate cancer
  • overdiagnosis
  • STARD
03

In context

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

This study's planned enrollment of 450 is above the median of 200 across 1,311 observational studies indexed under Prostatic Neoplasms.

Browse Prostatic Neoplasms studies →

Lead sponsor

Shanghai East Hospital is the lead sponsor of 95 studies on the registry; 50 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

patients who suspected to have prostate cancer

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age >= 40 years;
  2. Serum total PSA > 4.0 ng/mL and/or abnormal digital rectal examination;
  3. -naïve;
  4. Pre-biopsy 3.0-T multiparametric MRI demonstrating at least one suspicious lesion (PI-RADS v2.1 score 3-5);
  5. Fit for transperineal or transrectal prostate biopsy under local, regional, or general anaesthesia;
  6. Written .

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment for prostate cancer (surgery, radiotherapy, focal therapy, or androgen-deprivation therapy), or use of 5-alpha-reductase inhibitors within the preceding 6 months;
  2. Acute prostatitis or active urinary tract infection;
  3. to MRI (e.g., incompatible implants, severe claustrophobia);
  4. Severe coagulation disorders or uncorrectable bleeding tendency;
  5. History of major anorectal surgery precluding safe insertion of the endorectal ultrasound probe (where transrectal guidance is used);
  6. Any other condition that, in the investigator's judgement, makes the participant unsuitable for the trial.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
450 participants (estimated)
Target follow-up
30 Days
Patient registry
Yes

Groups and cohorts

  • Biopsy-naïve men with suspected prostate cancer

    Men undergoing standard-of-care combined targeted plus systematic prostate biopsy; every core undergoes ex vivo EndoScell fluorescence microscopy (index test) followed by FFPE histopathology (reference standard). Device results are not used for patient care.

    Diagnostic Test: Ex vivo real-time fluorescence microscopy of prostate biopsy cores (EndoScell system, model MES-1000P)

Interventions

  • Diagnostic testEx vivo real-time fluorescence microscopy of prostate biopsy cores (EndoScell system, model MES-1000P)

    Fresh biopsy cores are stained with fluorescein sodium (30 s) and methylene blue (30 s), scanned in contact mode within 5 minutes per core, and categorised on a three-tier scale; the tissue then proceeds to routine FFPE histopathology unchanged. The test is performed on excised tissue only and does not influence clinical management.

06

What researchers measure

Primary outcomes

  1. Patient-level sensitivity of the EndoScell system for clinically significant prostate cancer

    Proportion of reference-positive participants (any core with ISUP grade group \>=2 on FFPE histopathology) with at least one core read as Category 1 (suspected clinically significant prostate cancer) on the index test; reported with exact (Clopper-Pearson) 95% confidence interval in the intention-to-diagnose population.

    Time frame: Index test on Day 0; reference standard completed Day 7-14

  2. Patient-level negative predictive value (NPV) of the EndoScell system

    Proportion of participants with no Category 1 core who are reference-negative; exact 95% CI.

    Time frame: Index test on Day 0; reference standard completed Day 7-14

  3. Patient-level positive predictive value (PPV) of the EndoScell system

    Proportion of participants with at least one Category 1 core who are reference-positive (ISUP grade group \>=2 on FFPE); exact 95% CI.

    Time frame: Index test on Day 0; reference standard completed Day 7-14

  4. Patient-level specificity of the EndoScell system for clinically significant prostate cancer

    Proportion of reference-negative participants with no core read as Category 1; equivocal (Category 2) readings are grouped with test-negative in the primary analysis, with worst-case/best-case/exclusion sensitivity analyses prespecified; exact 95% CI.

    Time frame: Index test on Day 0; reference standard completed Day 7-14

Secondary outcomes

  1. Core-level diagnostic concordance

    Per-core sensitivity, specificity, PPV and NPV of the index test against FFPE histopathology, overall and stratified by core origin (targeted vs systematic), with cluster-robust 95% CIs from a generalised estimating equation (logit link, exchangeable correlation) accounting for within-patient clustering.

    Time frame: Index test on Day 0; reference standard completed Day 7-14

  2. Biopsy-sparing rate of the simulated "Positive-then-Stop" pathway

    Proportion of participants in whom systematic biopsy would have been omitted (any targeted core read as Category 1), and the corresponding proportion of systematic cores avoided; prespecified deterministic simulation, exact 95% CIs. Hypothesis-generating; does not alter patient care.

    Time frame: Simulation performed after database lock (estimated December 2028)

  3. Overdiagnosis reduction in the simulated pathway

    Number and proportion of ISUP grade group 1 diagnoses that would have been averted by omitting systematic biopsy after a positive intraoperative reading; exact 95% CI.

    Time frame: Simulation performed after database lock (estimated December 2028)

  4. Clinically significant prostate cancer miss rate in the simulated pathway

    Number and proportion of reference-positive participants who would have been missed under the simulated pathway (targeted cores negative on both index test and FFPE, with csPCa found only in systematic cores); exact 95% CI.

    Time frame: Simulation performed after database lock (estimated December 2028)

  5. Net benefit of the simulated pathway (decision-curve analysis)

    Decision-curve analysis with patient-level bootstrap (1000 resamples) comparing three strategies (combined biopsy for all; targeted biopsy alone; Positive-then-Stop) across threshold probabilities.

    Time frame: Simulation performed after database lock (estimated December 2028)

  6. Inter-reader agreement of index-test readings

    Cohen's kappa (three-tier scale and dichotomised Category 1 vs 0/2) and percent agreement between two blinded technicians re-interpreting a random 20% subset of archived scan videos (\~900-1200 cores).

    Time frame: Video re-reading after completion of enrolment (estimated 2028)

  7. Tissue-integrity (tissue-compromise) rate

    Proportion of cores flagged by uropathologists as degraded, unreadable, or inadequate for definitive H\&E/IHC evaluation attributable to the staining/scanning procedure; one-sided upper 95% confidence bound compared against the 1% acceptability benchmark.

    Time frame: Day 7-14 (pathology reporting)

  8. Operational performance of the index test

    Per-core scanning time, extraction-to-fixation interval, equivocal (Category 2) rate, and device/scan failure rate, summarised descriptively by centre and calendar quarter.

    Time frame: Day 0

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — De-identified participant-level data and the signed statistical analysis plan will be made available on reasonable request to the corresponding author, subject to a methodologically sound proposal and a signed data-access agreement.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Beginning 12 months after publication of the primary results, for a period of 5 years.

Access criteria: Proposals will be reviewed by the Trial Steering Committee; access requires approval and a data-access agreement.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2028, 24 months later.

Of 542 non-industry observational studies under Prostatic Neoplasms, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 162. This study's planned 24 months is below that.

Counting every sponsor, half of 651 studies reached it within 60 months; a quarter within 29 and three quarters within 141.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2026
First posted
Sep 29, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Dec 1, 2028
CompletionEst.
Jan 1, 2029
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07846592
Lead sponsor
Shanghai East Hospital
Responsible party
Sponsor
First posted
Sep 29, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Dec 1, 2028 (estimated)
Completion
Jan 1, 2029 (estimated)
Last update
Sep 29, 2026

Study contacts

biming He
Contact
190589109@qq.com
15502139410
haifeng wang
Contact
190589109@qq.com
86-13681750891
haifeng wang
study chair · Changhai Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion